Atriva: Targeting Patients, Not Virus, Is The Way Forward In Flu

Emerging Company Profile: Four-year-old Atriva Therapeutics GmbH is developing a drug to prevent the proliferation of flu virus by transiently inhibiting one of the patient’s own cellular processes, a host-mediated novel mechanism of action that could be effective against a range of respiratory virus infections.

Emerging Company Profile Regular column feature image Version 2

The Tübingen, Germany-based biotech Atriva Therapeutics GMBH is aiming to move its host-targeting anti-flu MEK inhibitor, ATR-002, into initial clinical studies in 2019, and believes the molecule’s novel mode of action could offer advantages over other approaches in the treatment of influenza, including universal flu vaccines and next-generation virus-targeted small molecules.

The company, which boasts an experienced management team and serial entrepreneur Rainer Lichtenberger as CEO, also is attracting the interest...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Start-Ups & SMEs

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

Abivax Over The Moon As Obefazimod Storms Phase III

 
• By 

Stock shoots up over 460% on positive results in two ulcerative colitis trials of the oral first-in-class candidate.

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

More from Business

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Roche Keen To Cut Out The Middle Men On US Pricing

 
• By 

The Swiss giant has been talking to the US government about selling medicines directly to patients.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.